📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 18:50
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Decipher Labs Q1 FY27: Revenue drops 17% to ₹2.41 Cr; Quarterly Loss is 36% of Market Cap
Decipher Labs reported a weak Q1 FY27 with consolidated revenue falling 17.4% YoY to ₹2.41 Cr. The company remains deeply in the red with a consolidated net loss of ₹2.19 Cr, which represents a significant 36.5% of its current ₹6 Cr market capitalization. Revenue is now almost entirely dependent on Consultancy Services (₹2.41 Cr), as the Pharmaceutical segment revenue collapsed to a negligible ₹0.40 Lakhs. High fixed costs remain a critical issue, with employee benefit expenses of ₹2.76 Cr exceeding the total revenue generated during the quarter.
Confidence: HIGH
What changedThe company released its revised Q1 FY27 results, confirming a continued decline in revenue and persistent net losses despite a shift toward consultancy services.
Why it mattersThe near-total collapse of the pharmaceutical segment revenue and high employee costs relative to the top line indicate a struggling business model that is rapidly eroding shareholder value.
Consolidated Revenue (Q1): ₹2.41 CrConsolidated Net Loss (Q1): ₹2.19 CrLoss vs Market Cap: ~36.5%Employee Expenses: ₹2.76 CrPharma Segment Revenue: ₹0.40 LakhsConsultancy Segment Revenue: ₹2.41 Cr
📅 Short termThe stock is likely to remain under pressure given the significant quarterly loss and the lack of growth in the core pharmaceutical business.
📈 Long termThe structural shift to a consultancy-led model has not yet achieved the scale required for profitability, posing long-term sustainability risks.
⚠ Risk flags
- High employee cost-to-revenue ratio (114%)
- Negligible revenue from core pharma segment
- Quarterly loss is a high percentage of market cap
- Persistent negative operating margins
Key Highlights
Consolidated revenue from operations declined to ₹2.41 Cr from ₹2.92 Cr in the same quarter last year.
Net loss for the quarter stood at ₹2.19 Cr, narrowing from a loss of ₹3.43 Cr in Q1 FY26.
Employee benefit expenses reached ₹2.76 Cr, accounting for 114.5% of the total revenue from operations.
Pharmaceutical segment revenue saw a near-total wipeout, falling to just ₹0.40 Lakhs from ₹67.50 Lakhs YoY.
Consultancy services segment revenue grew slightly to ₹2.41 Cr from ₹2.25 Cr in the year-ago period.
👀 What to Watch
Investors should monitor the company's cash burn rate and potential for capital infusion, as quarterly losses are extremely high relative to its market capitalization. Watch for any recovery in the pharmaceutical segment or further scaling in consultancy to cover high overheads.
Decipher Labs Reports Q1 FY27 Net Loss of ₹2.19 Cr; Appoints New Independent Director
Decipher Labs reported a consolidated net loss of ₹2.19 crore for the quarter ended June 30, 2026, which is a narrowing from the ₹3.43 crore loss in the same quarter last year. Consolidated revenue from operations declined 17.4% year-on-year to ₹2.41 crore from ₹2.92 crore. The company remains under significant financial pressure, with quarterly losses representing approximately 36.5% of its total market capitalization. Additionally, the board appointed Mr. Bhupendralal Waghray, a former government tax official, as an Independent Director for a five-year term.
Confidence: HIGH
What changedThe company reported its first-quarter financial results for FY27 and restructured its board with a new independent director appointment.
Why it mattersThe company continues to operate at a loss with declining revenues, and the quarterly loss is disproportionately large compared to its market cap, indicating high financial risk.
Q1 FY27 Consolidated Revenue: ₹2.41 CrQ1 FY27 Consolidated Net Loss: ₹2.19 CrQuarterly Loss vs Market Cap: ~36.5%Revenue Growth (YoY): -17.4%Promoter Holding: 16.43%
📅 Short termThe stock may face pressure due to continued losses and a shrinking revenue base reported in the Q1 results.
📈 Long termThe long-term outlook remains challenging unless the company can significantly scale its consultancy or pharmaceutical trading operations to achieve profitability.
⚠ Risk flags
- Persistent net losses
- High quarterly loss relative to market capitalization
- Declining year-on-year revenue
- Low promoter holding (16.43%)
Key Highlights
Consolidated revenue for Q1 FY27 decreased to ₹2.41 crore from ₹2.92 crore in Q1 FY26.
Net loss for the quarter stood at ₹2.19 crore, compared to a loss of ₹3.43 crore in the previous year's corresponding period.
Total expenses of ₹4.70 crore for the quarter significantly exceeded total income of ₹2.51 crore.
Consultancy services segment revenue on a standalone basis fell to ₹9.41 lakh from ₹17.15 lakh YoY.
Mr. Bhupendralal Waghray appointed as Additional Director (Independent) for a 5-year term effective August 13, 2026.
👀 What to Watch
Investors should monitor the company's cash burn and the performance of its consultancy segment, as current quarterly losses are extremely high relative to its ₹6 crore market valuation.
Rs 2.19 Cr Net Loss in Q1; Revenue drops 17% YoY to Rs 2.41 Cr
Decipher Labs reported a consolidated net loss of Rs 2.19 Cr for the quarter ended June 30, 2026, compared to a loss of Rs 3.43 Cr in the same period last year. Revenue from operations declined 17.4% YoY to Rs 2.41 Cr from Rs 2.92 Cr. A critical concern for investors is that employee benefit expenses at Rs 2.76 Cr exceeded the total revenue from operations (114.5% of revenue). The company also appointed Mr. Bhupendralal Waghray, a former government officer, as an Independent Director for a five-year term.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, showing a continued trend of operational losses and a shrinking revenue base compared to the previous year.
Why it mattersWith a market capitalization of only Rs 6 Cr and persistent losses, the company's financial health is fragile; the high fixed costs relative to revenue pose a significant risk to its survival.
Revenue (Q1 FY27): Rs 2.41 CrNet Loss (Q1 FY27): Rs 2.19 CrEmployee Cost vs Revenue: 114.5%Loss vs Market Cap: ~36.5%Revenue vs TTM Revenue: ~17.2%
📅 Short termNegative sentiment is expected due to the continued net loss and the fact that operating expenses remain significantly higher than revenue.
📈 Long termThe company faces structural challenges in scaling its consultancy and pharma segments to achieve break-even, compounded by a very low promoter holding of 16.4%.
⚠ Risk flags
- Operating expenses exceed total revenue
- Low promoter holding (16.4%)
- Micro-cap liquidity risk
- Persistent quarterly losses
Key Highlights
Consolidated net loss of Rs 2.19 Cr for Q1 FY27, representing ~36% of the company's current market cap
Revenue from operations fell to Rs 2.41 Cr, a 17.4% decline from Rs 2.92 Cr in Q1 FY26
Employee benefit expenses stood at Rs 2.76 Cr, which is 114.5% of the total revenue from operations
Total expenses of Rs 4.70 Cr significantly outpaced total income of Rs 2.51 Cr
Appointment of Bhupendralal Waghray as Additional Director (Independent) effective August 13, 2026
👀 What to Watch
Investors should monitor the company's ability to rationalize its high employee costs and overheads, which currently exceed its total revenue, making the business model unsustainable in its current form.
Decipher Labs Reports Q1 Net Loss of ‣2.19 Cr; Appoints New Independent Director
Decipher Labs reported a consolidated net loss of ‣2.19 Cr for Q1 FY27, narrowing from a ‣3.43 Cr loss in the same period last year. Revenue from operations declined 17.4% YoY to ‣2.41 Cr, while total expenses of ‣4.70 Cr continued to exceed total income. The company's employee benefit expenses alone (‣2.76 Cr) were higher than its total revenue from operations. Additionally, the board appointed Mr. Bhupendralal Waghray, a former government tax official, as an Independent Director for a five-year term.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results showing continued losses and appointed a new Independent Director with a background in tax administration.
Why it mattersFor a micro-cap company with a ‣6 Cr market cap, a quarterly loss of ‣2.19 Cr is highly material and indicates severe operational stress and potential erosion of net worth.
Consolidated Revenue (Q1): ‣2.41 CrConsolidated Net Loss (Q1): ‣2.19 CrEmployee Cost to Revenue Ratio: 114.4%Q1 Revenue vs TTM Revenue: 17.2%
📅 Short termNegative sentiment is expected due to the continued mismatch between revenue and high fixed costs, alongside a YoY decline in top-line performance.
📈 Long termThe company faces structural challenges with persistent losses and a very small scale of operations; the long-term outlook remains weak without a major capital infusion or business pivot.
⚠ Risk flags
- Persistent operational losses
- Employee costs exceeding total revenue
- Low promoter holding (16.4%)
- Micro-cap liquidity risk
Key Highlights
Consolidated revenue from operations fell to ‣2.41 Cr from ‣2.92 Cr in the year-ago quarter.
Net loss for the quarter stood at ‣2.19 Cr, representing a significant 36.5% of the company's current ‣6 Cr market capitalization.
Employee benefit expenses reached ‣2.76 Cr, accounting for 114.4% of the quarterly revenue from operations.
Standalone operations remain negligible with revenue of only ‣9.81 Lakhs for the quarter.
Appointment of Mr. Bhupendralal Waghray as Independent Director effective August 13, 2026.
👀 What to Watch
Investors should monitor the company's ability to control employee costs and scale its consultancy segment, as current operations are not generating enough revenue to cover basic fixed expenses.
